Compare Nike Inc (NKE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nike Inc trades at $42.96 (market cap $64.49B), while Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Nike Inc pays a 3.77% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NKE | VRTX | |
|---|---|---|
Market Cap | $64.49B | $121.95B |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $79.24 | $529.59 |
52-Week Low | $40.75 | $366.54 |
Enterprise Value | $66.49B | $116.69B |
Dividend Yield | 3.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $43.76, down 1.82% on the day, with a neutral technical signal and bullish moving averages. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.72 surpassing the $0.11 estimate. Revenue declined to $46.31B in 2025, while net income margin compressed to 6.7%. The stock holds a consensus analyst price target of $50.80, with 49% of analysts rating it a Buy. A dividend of $0.41 is scheduled for payment on July 1, 2026.
Nike's outlook is mixed: strong brand equity and earnings beats support upside potential, but revenue pressures and margin compression pose risks. Investors face trade-offs between valuation support and execution challenges in key markets like China. The stock's current discount to consensus target suggests cautious optimism amid turnaround efforts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
